| |
|
|
|
|
|
|
|
Epigenetics
22nd September 2010
NHLI,
Kensington, London |
|
Programme: |
|
09.00 |
Arrival, Registration
and Coffee |
|
|
|
Session 1 - Introducing Epigenetics - Chair – Richard Armer,
Lectus Therapeutics |
|
|
|
|
10.00
|
Karl Nightingale, Birmingham Medical
School
Fundamental Biology of Epigenetics |
|
10.45 |
Nessa Carey, Cellcentric, UK
Therapeutic
Opportunities in Epigenetics |
|
11.30 |
Gerard Drewes, Cellzome AG, Germany
Chemical Proteomics
Tools for Drug Discovery in Epigenetics |
|
|
|
|
12.15 |
Lunch |
|
|
|
|
Session 2 - Marketed Medicines from Epigenetics - Chair – Ruth Lock, Novartis |
|
|
|
|
13.30 |
Thomas Miller, Merck, USA
Zolinza (Vorinostat,
SAHA) – Case History |
|
14.15 |
Pierre Wijermans, Haga Hospital,
Netherlands
Dacogen (Decitabine) – Case History |
|
|
|
|
15.00 |
Tea |
|
|
|
|
Session 3 - Epigenetics – the Next Wave - Chair – Phil Jeffrey, GSK |
|
|
|
|
15.30 |
Stephen Shuttleworth, Karus, UK
Second
Generation HDAC inhibitors |
|
16.15 |
Jason Witherington, GSK, UK
Bromodomains – a
tractable Epigenetic target for drug discovery |
|
|
|
|
17.00 |
Close |
|
|
|
Back
to Menu
|
|
|
|
|
|
|
